{"id":35707,"date":"2019-02-20T11:53:02","date_gmt":"2019-02-20T11:53:02","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=35707"},"modified":"2019-02-20T16:43:00","modified_gmt":"2019-02-20T16:43:00","slug":"27th-international-workshop-on-hiv-drug-resistance-and-treatment-strategies","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/35707","title":{"rendered":"27th International Workshop on HIV Drug Resistance and Treatment Strategies"},"content":{"rendered":"

22\u201323 October 2018, Johannesburg<\/span><\/strong><\/p>\n

Introduction<\/span><\/h2>\n

The resistance workshop focuses specifically on the growing issue of resistance to antiretrovirals, especially in low- and middle-income countries (LMICs). <\/span><\/b><\/p>\n

It comprises two days of invited plenary presentations and abstract-driven oral and poster sessions followed by a half-day workshop.<\/span><\/p>\n

The scientific committee is especially interested in research and topics from LMICs and the 2018 workshop (as well as the previous one) was appropriately held in Johannesburg, with The Southern African HIV Clinicians Society as secretariat. This arrangement continues with the 2019 resistance workshop to be held in October.<\/span><\/p>\n

Topics at the 2018 workshop included, the clinical implications of resistance in LMICs, the dolutegravir dilemma (much discussion on the risk\/benefits of potential safety signal vs increasing NNRTI resistance), new generation sequencing, and new and long acting drugs.
\n<\/span>http:\/\/www.hivresistance2018.co.za<\/a><\/span><\/p>\n

The programme is online at:
\nhttp:\/\/www.hivresistance2018.co.za\/wp-content\/uploads\/2018\/11\/HIVDR-2018-programme-web.pdf<\/a> (PDF)<\/span><\/p>\n

Some, but not all, of the presentations can be found at:
\nhttp:\/\/www.hivresistance2018.co.za\/programme\/<\/a><\/span><\/p>\n

Articles in this issue of HTB include:<\/p>\n